Glycemic Control in Patients After Initiation of Treatment for Vision-Threatening Diabetic Retinopathy
- PMID: 38770084
- PMCID: PMC11102714
- DOI: 10.1177/24741264241232191
Glycemic Control in Patients After Initiation of Treatment for Vision-Threatening Diabetic Retinopathy
Abstract
Purpose: To understand changes in glycemic control in patients being managed with vision-threatening diabetic retinopathy (DR). Methods: A retrospective cohort study was performed of patients with type 2 diabetes mellitus who were at least 18 years old. Patients who started treatment for vision-threatening DR were matched with controls based on age, sex, race/ethnicity, duration of diabetes, history of diabetes, and history of hypertension. The primary outcome was the difference in hemoglobin A1c (HbA1c) change after 12 months between cases and controls. Results: Four hundred fifty patients were included (225 cases paired with 225 controls); 58.7% of patients were men, and 33.8% were Hispanic. The mean (±SD) baseline HbA1c was 8.12% ± 1.57%. Patients receiving retinal interventions did not experience a significant change in HbA1c compared with controls 12 months after starting treatment (0.11% ± 1.51% vs -0.02% ± 1.52%; P = .31). In addition, there was not a significant difference in HbA1c change between cases and controls when considering the number of interventions: 2 or fewer interventions (+0.08% ± 1.30% vs -0.07% ± 1.15%; P = .46), 3 to 6 interventions (+0.41% ± 1.71% vs +0.01% ± 2.0%; P = .08), and 7 or more interventions (-0.17% ± 1.49% vs 0.0% ± 1.31%; P = .50). Conclusions: Patients who received treatment for vision-threatening DR did not experience a change in HbA1c. Increasing number of retinal interventions also did not appear to impact glycemic control. There appears to be a missed opportunity for improving diabetes management in patients with vision-threatening DR.
Keywords: diabetes mellitus; diabetic macular edema; hemoglobin A1c; intravitreal injection; laser; proliferative diabetic retinopathy; vision-threatening diabetic retinopathy.
© The Author(s) 2024.
Conflict of interest statement
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Jun Wu receives research support from GlaxoSmithKline, Genentech, and VoxelCloud. Dr. Modjtahedi receives research support from Genentech and VoxelCloud. Dr. Pio receives research support from Genentech, VoxelCloud, and Allergan.
References
LinkOut - more resources
Full Text Sources
Miscellaneous
